TIAA CREF Investment Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

TIAA CREF Investment Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$363K	Sell	3,975 -2	-0.1%	-$139	﹤0.01%	2717
2018 Q4	$222K	Sell	3,977 -81	-2%	-$6.15K	﹤0.01%	2854
2018 Q3	$483K	Sell	4,058 -2,328	-36%	-$270K	﹤0.01%	2730
2018 Q2	$652K	Buy	6,386 +2,470	+63%	+$306K	﹤0.01%	2661
2018 Q1	$508K	Buy	3,916 +869	+29%	+$95K	﹤0.01%	2727
2017 Q4	$296K	Sell	3,047 -152	-5%	-$20.4K	﹤0.01%	2945
2017 Q3	$471K	Sell	3,199 -240	-7%	-$45.1K	﹤0.01%	2851
2017 Q2	$553K	Buy	3,439 +2,978	+646%	+$468K	﹤0.01%	2818
2017 Q1	$73K	Hold	461	–	–	﹤0.01%	3057
2016 Q4	$56K	Buy	+461	New	+$64.6K	﹤0.01%	3102

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

TIAA CREF Investment Management's SYRS Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Syros Pharmaceuticals, Inc. Common Stock (SYRS) stake by 0.05% in Q1 2019, selling an estimated $139 and leaving 3,975 shares worth $363K. The position accounts for ﹤0.01% of the portfolio, ranked #2717.

TIAA CREF Investment Management first reported a position in SYRS in Q4 2016 and has held it in 10 quarters since. The position peaked at $652K in Q2 2018. 65 funds tracked by Wall St. Rank hold SYRS as of Q1 2019.

TIAA CREF Investment Management held 3,975 shares of Syros Pharmaceuticals, Inc. Common Stock worth $363K as of Q1 2019.
TIAA CREF Investment Management sold 2 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $139.
Syros Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2717 holding.
TIAA CREF Investment Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2016 and has held it in 10 quarters since.
TIAA CREF Investment Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $652K in Q2 2018.
65 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.